Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Examining the Combination of Lenalidomide and Azacitidine for Relapsed/Refractory CLL and SLL

This study has been terminated.
(anticipated results not seen and population not seen)
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Hackensack University Medical Center
ClinicalTrials.gov Identifier:
NCT01241786
First received: November 15, 2010
Last updated: November 7, 2012
Last verified: November 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2011
  Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)